EA201590744A1 - Лечение рака tor киназными ингибиторами - Google Patents

Лечение рака tor киназными ингибиторами

Info

Publication number
EA201590744A1
EA201590744A1 EA201590744A EA201590744A EA201590744A1 EA 201590744 A1 EA201590744 A1 EA 201590744A1 EA 201590744 A EA201590744 A EA 201590744A EA 201590744 A EA201590744 A EA 201590744A EA 201590744 A1 EA201590744 A1 EA 201590744A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tor
cancer
torring
kinase inhibitors
prostate cancer
Prior art date
Application number
EA201590744A
Other languages
English (en)
Other versions
EA029164B1 (ru
Inventor
Дебора Мортенсен
Хитер Рэймон
Рама К. Нарла
Кристен Мей Хедж
Кимберли Элизабет Фулц
Тосия Цудзи
Original Assignee
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA201590744A1 publication Critical patent/EA201590744A1/ru
Publication of EA029164B1 publication Critical patent/EA029164B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к способам лечения или предотвращения рака предстательной железы, включающим введение эффективного количества TOR киназного ингибитора пациенту, имеющему рак предстательной железы.
EA201590744A 2012-10-18 2013-10-17 Лечение рака tor киназными ингибиторами EA029164B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201590744A1 true EA201590744A1 (ru) 2015-11-30
EA029164B1 EA029164B1 (ru) 2018-02-28

Family

ID=50023830

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590744A EA029164B1 (ru) 2012-10-18 2013-10-17 Лечение рака tor киназными ингибиторами

Country Status (19)

Country Link
US (1) US20140113904A1 (ru)
EP (1) EP2908814B1 (ru)
JP (3) JP2015534981A (ru)
KR (2) KR102267927B1 (ru)
CN (2) CN105050601A (ru)
AU (1) AU2013202768B2 (ru)
BR (1) BR112015008834A2 (ru)
CA (1) CA2888609C (ru)
EA (1) EA029164B1 (ru)
ES (1) ES2777936T3 (ru)
IL (1) IL238326B (ru)
MX (1) MX368407B (ru)
MY (1) MY176599A (ru)
NI (1) NI201500055A (ru)
PH (1) PH12015500867B1 (ru)
SG (2) SG10201810575WA (ru)
UA (1) UA117000C2 (ru)
WO (1) WO2014062878A2 (ru)
ZA (1) ZA201503105B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
MX2021001186A (es) * 2015-11-20 2022-10-11 Forma Therapeutics Inc Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值，总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
BRPI0717773A2 (pt) 2006-10-19 2013-11-05 Signal Pharm Llc Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
ES2613664T3 (es) * 2009-10-26 2017-05-25 Signal Pharmaceuticals, Llc Procedimientos de síntesis y purificación de compuestos de heteroarilo
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Also Published As

Publication number Publication date
WO2014062878A9 (en) 2014-12-18
KR20150070319A (ko) 2015-06-24
KR102267927B1 (ko) 2021-06-21
AU2013202768A1 (en) 2014-05-08
EP2908814A2 (en) 2015-08-26
ZA201503105B (en) 2016-11-30
ES2777936T3 (es) 2020-08-06
SG11201502999YA (en) 2015-05-28
MX2015004874A (es) 2015-08-05
PH12015500867A1 (en) 2015-06-22
JP2015534981A (ja) 2015-12-07
BR112015008834A2 (pt) 2017-07-04
NI201500055A (es) 2015-09-10
JP7162543B2 (ja) 2022-10-28
CN110721186A (zh) 2020-01-24
KR20200108923A (ko) 2020-09-21
JP2019081771A (ja) 2019-05-30
WO2014062878A3 (en) 2014-06-26
PH12015500867B1 (en) 2015-06-22
CA2888609C (en) 2020-12-01
IL238326B (en) 2018-03-29
EP2908814B1 (en) 2019-12-25
EA029164B1 (ru) 2018-02-28
US20140113904A1 (en) 2014-04-24
CN105050601A (zh) 2015-11-11
UA117000C2 (uk) 2018-06-11
KR102157914B1 (ko) 2020-09-18
WO2014062878A2 (en) 2014-04-24
JP2021050213A (ja) 2021-04-01
CA2888609A1 (en) 2014-04-24
SG10201810575WA (en) 2019-01-30
IL238326A0 (en) 2015-06-30
AU2013202768B2 (en) 2015-11-05
MY176599A (en) 2020-08-18
MX368407B (es) 2019-10-02

Similar Documents

Publication Publication Date Title
PH12018502234B1 (en) Treatment of cancer with tor kinase inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201890768A3 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
PH12014502047A1 (en) Treatment of cancer with tor kinase inhibitors
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EA201591509A1 (ru) Ингибиторы cdc7
MX2015004016A (es) Inhibidores de azaquinazolina de la proteina quinasa c atipica.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
EA201491581A1 (ru) Везикулярные композиции
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM